Publications by authors named "Pellicano M"
Article Synopsis
- * Treatment focuses on reducing spleen size and alleviating symptoms, with patients evaluated as lower or higher risk for transplant eligibility; those not eligible usually receive long-term JAK inhibitor therapy.
- * Newer JAK inhibitors and combination treatments are under investigation to address the limitations of current therapies, such as limited efficacy and adverse effects, highlighting the need for ongoing research in this area.
Article Synopsis
- This study examined the effects of D-VTd induction therapy on recovery after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma (NDMM).
- Sixty patients received D-VTd while 80 others received VTd as a control, with results showing that D-VTd led to a slightly longer time for neutrophil and platelet recovery.
- Despite delayed engraftment in the D-VTd group and a higher incidence of febrile neutropenia, the study concluded that D-VTd does not negatively affect overall transplant safety outcomes.
Article Synopsis
- - Balloon aortic valvuloplasty (BAV) is a procedure used for patients with severe aortic valve stenosis, either as preparation for trans-catheter aortic valve replacement (TAVR) or alone in certain cases; the study focused on the newly available Mammoth balloon catheter (BC) used in this context.
- - A retrospective analysis was conducted on patients treated with the Mammoth BC at a hospital in Milan, where technical success was defined by the ability to successfully deploy and inflate the catheter without significant complications like injury or stroke.
- - The results showed a 100% technical success rate in 121 procedures with no complications attributed to the Mammoth BC; however, some patients in the stand-alone group
Article Synopsis
- Coronary access (CA) and percutaneous coronary intervention (PCI) can be more difficult after valve-in-valve transcatheter aortic valve replacement (ViV-TAVR), especially with certain valve designs.* -
- A study found that the ACURATE neo2 valve led to significantly better success rates for both CA (96.7%) and PCI (98.3%) compared to the Evolut PRO+ valve (75% and 85%, respectively).* -
- The design differences between the valves affected procedural approaches, with ACURATE neo2 allowing for easier access due to a greater valve-to-anatomy distance.*
Introduction: Over the past two decades, transcatheter aortic valve replacement (TAVR) has expanded its application across all surgical risk levels, including low-risk patients, where, due to longer life expectancy, reducing common pitfalls of TAVR is essential. To address these needs, many technological advancements have been developed. Myval and the new generation Myval Octacor (Meril Life Sciences Pvt.
View Article and Find Full Text PDFIntroduction: Drug-coated balloon (DCB) is an established treatment option for in-stent restenosis and small vessel, de novo, coronary artery disease (CAD). Although the use of this tool is increasing in everyday practice, data regarding performance in the treatment of de novo, large vessel CAD (LV-CAD) is still lacking. A systematic review and meta-analysis were conducted to evaluate the efficacy and safety of DCB versus drug-eluting stent (DES) in this setting.
View Article and Find Full Text PDFThe optimal timing to perform percutaneous coronary interventions (PCIs) in patients undergoing transcatheter aortic valve replacement (TAVR) is not well established. In this meta-analysis, we aimed to compare the outcomes of patients undergoing PCI before versus after TAVR. A comprehensive literature search was performed including Medline, Embase, and Cochrane electronic databases up to 5 April 2024 for studies that compared PCI before and after TAVR reporting at least one clinical outcome of interest (PROSPERO ID: CRD42023470417).
View Article and Find Full Text PDFBackground: The new balloon-expandable (BE) Myval transcatheter heart valves (THV) has shown promising early results with low paravalvular leak (PVL) and permanent pacemaker implantation (PPI) rates. Limited data are available regarding its long-term performance. We aimed to compare the 2-year clinical and echocardiographic outcomes of transcatheter aortic valve replacement (TAVR) using the self-expanding (SE) Evolut R and the BE Myval THVs.
View Article and Find Full Text PDFArticle Synopsis
- * A prospective study included 106 patients, with a focus on outcomes like cardiac death and revascularization, showing high procedural success and improvement in vessel dimensions post-treatment.
- * The study concluded that combining drug-eluting stents and drug-coated balloons could be a promising and safe alternative treatment method for de novo diffuse CAD.
Article Synopsis
- - The study focused on evaluating the performance of the ACURATE Neo2 transcatheter heart valve (THV) in patients with a horizontal aorta (HA), which is linked to worse outcomes after heart valve procedures.
- - Results showed that while both ACURATE Neo and Neo2 valves had similar success rates, the Neo2 valve significantly reduced the occurrence of moderate or severe paravalvular leak (PVL) compared to the Neo valve (5% vs. 15%).
- - The findings suggest that the Neo2 valve is a better option for patients with HA, offering improved PVL rates without compromising device success in the shorter term follow-up.
Article Synopsis
- - The study aimed to compare the effects of two antiplatelet medications, ticagrelor and prasugrel, on coronary blood flow and microvascular resistance in patients with stable coronary artery disease undergoing elective procedures.
- - Results showed that patients receiving ticagrelor exhibited significantly higher coronary blood flow and lower microvascular resistance after the procedure compared to those on prasugrel.
- - Additionally, ticagrelor treatment was linked to less myocardial injury, indicated by lower increases in troponin levels after the intervention, suggesting it may be more beneficial than prasugrel in this context.
Article Synopsis
- * A hybrid treatment strategy using a drug-eluting stent (DES) in the main branch and a drug-coated balloon in the side branch may lead to better outcomes by reducing stent length while providing strong anti-proliferative effects.
- * In a sub-study involving 50 patients treated with this hybrid approach, the procedure had a high success rate (96%) and showed promising safety with a low occurrence of complications, indicating it may be a viable option for treating true CBL.
Multiple myeloma (MM) is the main indication for autologous stem cell transplantation (ASCT). Novel supportive therapies (e.g.
View Article and Find Full Text PDFBackground: The first-generation ACURATE neo transcatheter heart valve (THV) (Boston Scientific) was associated with a non-negligible occurrence of moderate or greater paravalvular aortic regurgitation (AR) following transcatheter aortic valve replacement. To overcome this issue, the ACURATE neo2 iteration, which incorporates a taller outer skirt aimed at reducing the occurrence of paravalvular AR, has recently been developed.
Objectives: The aim of this study was to assess the efficacy and safety of the ACURATE neo2 (Boston Scientific) THV in patients with severe aortic valve stenosis.
Background: Optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) of a bifurcation stenosis is still debated. We evaluated the impact of DAPT duration on clinical outcomes in all-comers patients undergoing bifurcation PCI included in the European Bifurcation Club (EBC) registry.
Methods: We enrolled 2284 consecutive patients who completed at least 18 months follow-up.
Background: Transcatheter aortic valve replacement (TAVR) is an effective treatment option for patients with severe, symptomatic AS, regardless of the transcatheter heart valve (THV) implanted. Prior studies demonstrated a higher device success with lower paravalvular leak (PVL) using the balloon-expandable (BE) Sapien/XT THV vs. a self-expanding (SE) THV.
View Article and Find Full Text PDFOver the last 15 years, the management of aortic valve disease has been changed by transcatheter aortic valve replacement, which has become the standard of care across the entire spectrum of surgical risk. As a result of continuous evolution of this technique, several next-generation transcatheter heart valves (THVs) have been developed to minimize procedural complications and improve patient outcomes. This review aims to provide an update on the new generation THVs and delivery systems.
View Article and Find Full Text PDFCoronary bifurcation lesion (CBL) is a common but challenging scenario in percutaneous coronary interventions. Drug-coated balloons (DCBs) are modern devices with attractive perspective in CBL treatment. In-stent restenosis, small vessel and diffuse de-novo coronary artery disease have been, so far, considered the ideal scenario for DCBs application.
View Article and Find Full Text PDFThis study aimed to explore the applicability of electronic-nose (E-nose) as a rapid method in discriminating samples of sweet cherry cv "Ferrovia" stored in high-CO (16% O + 20% CO + 64% N) or air (control) up to 21 days. Projection to Latent Structures (PLS) methods applied to E-nose data showed that fresh fruit and the packaged or unpackaged samples can be distinguished, according to both the storage condition and the storage days. Moreover, a correlation analysis between E-nose sensors and 45 volatile compounds were overall, obtained from all the investigated sweet cherry samples by Headspace Solid-Phase Microextraction (HS SPME) coupled to Gas Chromatography-Mass Spectrometry (GC-MS).
View Article and Find Full Text PDF